key: cord-0925882-ul092tbk authors: Marinella, Mark A. title: Indomethacin and resveratrol as potential treatment adjuncts for SARS‐CoV‐2/COVID‐19 date: 2020-05-15 journal: Int J Clin Pract DOI: 10.1111/ijcp.13535 sha: 944394d7b187d581c7259da05c1fe5f4a965258b doc_id: 925882 cord_uid: ul092tbk The ongoing pandemic due to severe acute respiratory syndrome coronavirus type 2 (SARS‐CoV‐2, also known as COVID‐19) has led to unprecedented challenges for the global healthcare system. This novel coronavirus disease phenotype ranges from asymptomatic carriage to fulminant cytokine storm with respiratory failure, polyorgan dysfunction, and death. Severe disease is characterized by exuberant inflammation resulting from high circulating cytokines such as interleukin‐6 (IL‐6) and tumor necrosis factor (TNF). These inflammatory mediators are responsible for the detrimental effects on the immune, hematologic, respiratory, renal, gastrointestinal and other body systems. In addition to inhibition of viral replication, blunting this inflammatory response before overt cytokine storm is important to improve outcomes. Although there are upcoming promising agents such as remdesivir and convalescent plasma, inexpensive, safe, and widely available adjunct treatments to ameliorate disease burden would be welcome. Two potential antiinflammatory agents include indomethacin, which has been shown in experimental models to decrease canine coronavirus (CCoV) levels in dogs and exhibit antiviral activity against several other viruses, and the polyphenol, resveratrol, a potent antioxidant that has shown antiviral activity against several viruses. Indomethacin is an inexpensive, non-selective cyclooxygenase (COX) inhibitor that inhibits COX-1 and COX-2, and is used to treat a variety of inflammatory conditions. Indomethacin is a potent antiinflammatory agent and inhibits COX enzymes more potently than aspirin. 4 Amici et al. showed that indomethacin possesses antiviral activity in vitro against severe acute respiratory syndrome coronavirus (SARS CoV) in monkey VERO cells as well as in vivo activity at relatively low doses (1 mg/kg) against canine coronavirus (CCoV) in dogs. 5 The authors concluded that indomethacin possesses direct antiviral activity for SARS CoV and CCoV by blocking viral RNA synthesis (>1,000-fold reduction in virus yield in CCoV infected dogs), independent of antiinflammatory effects. 5 Several in vitro and in vivo studies in animals have also demonstrated varying degrees of antiviral activity of indomethacin. Indomethacin has been shown to interrupt the viral life This article is protected by copyright. All rights reserved cycle of various herpesviruses, and may diminish latent infections by inhibiting prostaglandin synthesis, which is blocked by indomethacin and other nonsteroidal drugs. 6 Ray et al. demonstrated that COX-2 transcription increased after herpes simplex virus type I and pseudorabies virus infection of embryonic rat cells and that COX inhibitors decreased growth of the pseudorabies virus. 7, 8 Cytomegalovirus induces accumulation of COX-2 and indomethacin decreased cell-to-cell spread of CMV in cultured fibroblasts in vitro. 9 Bahrami and colleagues reported that indomethacin 25 mg three times a day eradicated hepatitis B virus DNA in seven human patients. 10 Other studies have shown that indomethacin induced inhibition of COX and antagonized mouse vesicular stomatitis virus encephalitis growth in vitro and in vivo. 11 As a final example, indomethacin reduced rotavirus infection in human intestinal Caco-2 cells, by inhibiting viral protein synthesis. 12 Although the activity of indomethacin in the above scenarios is mainly in vitro or in animal models, there is compelling data that indomethacin may be therapeutic in certain viral infections. Furthermore, this agent is available with predictable toxicity profiles and may be an option to consider in combatting human SARS-CoV-2. Indomethacin, however, can induce side effects such as gastritis, renal dysfunction and platelet dysfunction, 4 that could be detrimental to patients with severe SARS-CoV-2 infection, especially if they have multiorgan dysfunction resulting from cytokine storm. Furthermore, some authors have reported that NSAIDS such as ibuprofen may be detrimental in patients with novel coronavirus, causing more severe infection or lead to later complications such as empyema, prolonged hospital stay, or lung cavitation, as has been reported in patients with bacterial pneumonia. 13, 14 However, the WHO recently did not recommend against ibuprofen use for infection with SARS-CoV-2. 15 Studies have shown ibuprofen to decrease sputum IL-6 in cystic fibrosis patients 16 and synovial fluid IL-6 in patients with knee osteoarthritis, 17 which demonstrates that NSAIDS can lower IL-6 in human fluids. This lends biologic plausibility that COX inhibition with indomethacin could lower IL-6 levels in nasopharyngeal-respiratory tract secretions. Whether using lower doses of indomethacin (e.g., 25 mg three times daily) at first sign of infection (in outpatients after a positive nasopharynx swab) or for inpatients with adequate This article is protected by copyright. All rights reserved found that resveratrol was able to suppress pseudorabies virus (a herpesvirus affecting swine that causes fatal encephalitis as well as lung inflammation) in vitro by inhibiting intracellular viral multiplication. 25 Piglets inoculated with pseudorabies virus who were supplemented with resveratrol at different dose levels for seven days prior to infection, had significantly lower viral loads than the untreated group as well as significantly decreased death rates (90% survival in the resveratrol group, with no deaths in the higher dosed groups-30 mg/kg and 10 mg/kg had 100% survival; the low dose group of 3 mg/kg had 90% survival). 25 Since resveratrol has limited oral bioavailability, some authors have suggested nanoparticle formulations or combination with modified beta-glucan in aqueous solutions which may improve stability and absorption. 21, 26 Intranasal resveratrol and carboxymethyl-beta-glucan mixture administered to infants decreased symptoms of the common cold. 26 As a final example of the biologic therapeutic plausibility for resveratrol for viral and/or SARS-CoV-2 infection, resveratrol added to the diet of piglets for 21 days, decreased TNF-alpha levels and diminished diarrhea due to rotavirus. 27 Although there are no data for using resveratrol in humans infected with SARS-CoV-2, the above studies demonstrate that this compound may be an adjunctive antiviral agent to consider, especially based on the data published by Linn et al. showing activity against MERS-CoV in vitro. 23 Although dosing in humans is unknown, resveratrol is considered safe when taken at supplemental doses. Although randomized trial data are not yet available for indomethacin and resveratrol for treatment of or slowing progression of SARS-CoV-2 infection, these agents should be considered by the medical community as potentially worthy of further study as therapeutic adjuncts, given the relative safety, accessibility, and low cost. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status Vibrio vulnificus sepsis. Handbook of Cancer Emergencies Covid-19-navigating the uncharted Goodman and Gilman's Manual of Pharmacology and Therapeutics Indomethacin has a potent antiviral activity against SARS coronavirus Biological interactions between herpesviruses and cyclooxygenase enzymes Cyclooxygenase-1 and -2 are required for production of pseudorabies virus Inhibition of cyclooxygenase activity blocks cell-to-cell spread of human cytomegalovirus Accepted Article This article is protected by copyright. All rights reserved Effects of indomethacin on viral replication markers in asymptomatic carriers of hepatitis B: a randomized placebo controlled trial NSAID treatment suppresses VSV propagation in mouse CNS Inhibition of cyclooxygenase activity reduces rotavirus infection at a postbinding step Covid-19: ibuprofen should not be used for managing symptoms say doctors and scientistsl Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infection with reference to use of therapeutic and other drugs used in co-morbid diseases (Hypertension, diabetes, etc.) Updated: WHO now doesn't recommend avoiding ibuprofen for COVID-19 symptoms Use of ibuprofen to assess inflammatory biomarkers in induced sputum: implications for clinical trials in cystic fibrosis The effects of nonsteroidal anti-inflammatory drugs on clinical outcomes, synovial fluid cytokine concentration and signal transduction pathways in knee osteoarthritis. A randomized open label trial The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China A summary of selected phytonutrient dense foods: is there data? Metronomic Phytonutrition: How Daily, Regular Intake of Plant-Based Foods May Decrease Cancer Risk Accepted Article This article is protected by copyright. All rights reserved Antiviral activity of resveratrol Antiviral activity of resveratrol against human and animal viruses Antiviral effect of resveratrol in piglets infected with virulent pseudorabies virus Effective inhibition of MERS-CoV infection by resveratrol Antiviral effect of resveratrol in ducklings infected with virulent duck enteritis virus Antiviral properties of resveratrol against pseudorabies virus are associated with the inhibition of IkB kinase activation Resveratrol plus carboxymethyl-betaglucan in infants with common cold: a randomized double blind trial This article is protected by copyright. All rights reserved